LY3002813 – Biological drug to treat early symptoms of Alzheimer’s Disease

LY3002813 Biological drug to treat early symptoms of Alzheimer’s Disease (TRAILBLAZER-ALZ-2)

$

This study evaluates the safety and effectiveness of Donanemab in slowing the mental and functional changes of Alzheimer’s Disease.

$

This trial is not accepting new patients.

$

The safety of donanemab and any side effects you might have, whether donanemab can help slow the mental and functional changes of Alzheimer’s disease (AD), and whether donanemab can change the appearance of your brain on MRI and PET scans.

$

Basic Enrollment Criteria:

  • Age 60-85 years old, Male & Female
  • Willing to comply with study visits and requirements
$

Study Length:

  •  76-week main study period and 78 week extension period

Participate In This Study

Sign-up Here